Author:
Lasaga Miren,Río Paula,Vilas-Zornoza Amaia,Planell Nuria,Navarro Susana,Alignani Diego,Fernández-Varas Beatriz,Mouzo Daniel,Zubicaray Josune,Pujol Roser M.,Nicoletti Eileen,Schwartz Jonathan D.,Sevilla Julián,Ainciburi Marina,Ullate-Agote Asier,Surrallés Jordi,Perona Rosario,Sastre Leandro,Prosper Felipe,Gomez-Cabrero David,Bueren Juan A.
Abstract
Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in nonconditioned Fanconi anemia (FA) patients resulting from the proliferative advantage of corrected FA hematopoietic stem and progenitor cells (HSPC). However, it is not yet known if gene therapy can revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPC co-existing in the BM of gene therapy-treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC. This includes a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases; in this case, in FA characterized by BMF and cancer predisposition.
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献